| Literature DB >> 30925560 |
Jonathan S Jahr1, Nicole R Guinn2, David R Lowery3,4, Linda Shore-Lesserson5, Aryeh Shander6,7.
Abstract
Despite the exhaustive search for an acceptable substitute to erythrocyte transfusion, neither chemical-based products such as perfluorocarbons nor hemoglobin-based oxygen carriers have succeeded in providing a reasonable alternative to allogeneic blood transfusion. However, there remain scenarios in which blood transfusion is not an option, due to patient's religious beliefs, inability to find adequately cross-matched erythrocytes, or in remote locations. In these situations, artificial oxygen carriers may provide a mortality benefit for patients with severe, life-threatening anemia. This article provides an up-to-date review of the history and development, clinical trials, new technology, and current standing of artificial oxygen carriers as an alternative to transfusion when blood is not an option.Entities:
Year: 2021 PMID: 30925560 DOI: 10.1213/ANE.0000000000003957
Source DB: PubMed Journal: Anesth Analg ISSN: 0003-2999 Impact factor: 5.108